Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

Could these FTSE 100 giants boost your portfolio higher?

Should you be buying these three FTSE 100 (INDEXFTSE: UKX) stocks for their income potential?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 (INDEXFTSE: UKX) stocks can provide great returns for investors. Through income and growth the stocks can be a stable way to get rich slowly. 

Commodity giant

Glencore (LSE: GLEN) has been under the spotlight for over a year now. Commodity prices across the board fell sharply, which dragged the share price of Glencore down to all-time lows. However, since then the company has done a lot counter criticism of its business and it has come a long way since City analysts were saying it could go to zero. Since 1 January the share price has climbed 125% and analysts are now tagging the stock with price targets over 250p. The company has looked at the issue of its debt pile and divested a number of assets to pay off debt. I believe that the major mining company could be a good way to ride strengthening commodity prices that many expect in the next few years. The stock is coming from a very low price so it could see an explosive price rise soon. 

Defensive pharma

GlaxoSmithKline (LSE: GSK) is a favorite of UK income fund managers and quite rightly so. It holds great defensive qualities and I believe it has less risk than its FTSE 100 peer AstraZeneca. Glaxo shares are currently yielding over 4%, which is a decent income considering we live in a world of low interest rates. For income investors this looks like a top stock to own for its dividend and growth potential. The pipeline of new drugs that Glaxo has is very encouraging and the company believes there could be multiple blockbuster drugs on the way. This pipeline will add to profitability for the firm. While currently the shares are trading on 17 times forward price-to-earnings, Glaxo looks set to reap the rewards of its R&D success and I think the shares look cheap. 

UK housebuilding play

Persimmon (LSE: PSN) is about to become a great income stock due to the huge dividend scheme the company is about to begin. The shares are on a yield of over 5% and have nearly recovered since the Brexit vote shock. The UK has a fundamental housing shortage, which was addressed by Chancellor Philip Hammond this week. When setting out his new £5bn housing fund he said “my message today is clear: it’s time to get building”. This fund is for small businesses to build 25,000 homes by 2020 and 225,000 in the longer term. This is a clear indication that the housebuilding sector in the UK has a lot of work to do. Persimmon is a great way to play housebuilding in the UK and receive some income at the same time. 

I believe that these three giants will provide investors with good capital growth over the next few years and should outperform the wider market. In the case of Glaxo and Persimmon, investors will receive some chunky dividend payouts too. 

Jack Dingwall has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

My stock market crash list: 3 shares I’m desperate to buy

Market volatility may not be too far away so Edward Sheldon has been working on a list of high-quality shares…

Read more »

White middle-aged woman in wheelchair shopping for food in delicatessen
Investing Articles

Greggs’ shares became 43.5% cheaper this year! Is it time for me to take advantage

Greggs' shares have tanked in 2025, with profits tumbling since the start of the year. But could this secretly be…

Read more »

Light bulb with growing tree.
Investing Articles

What on earth is going on with ITM Power shares?

ITM Power shares have had an extraordinary few months. Our Foolish author looks at what's been going on and whether…

Read more »

A hiker and their dog walking towards the mountain summit of High Spy from Maiden Moor at sunrise
Investing Articles

2 cheap stocks that will continue surging in 2026, according to experts!

These UK shares have already surged 60% in 2025, yet if the forecasts are correct, there could be even more…

Read more »

Rolls-Royce engineer working on an engine
Investing Articles

Down 10%, could its nuclear ambitions save Rolls-Royce’s share price?

The Rolls-Royce share price may be in decline but it isn't time to panic-sell just yet. Mark Hartley looks at…

Read more »

Young black woman in a wheelchair working online from home
Investing Articles

Up 60% with a 4.6% yield! Is this the best growth and income stock in the UK?

Wickes Group continues to pay decent income while exhibiting the profitability of a growth stock. Is it the best of…

Read more »

Landlady greets regular at real ale pub
Investing Articles

Down 57%, is the Diageo share price a generational bargain?

Investment analyst Zaven Boyrazian has spotted an incoming catalyst in 2026 that could trigger a massive recovery for the Diageo…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Collapsing prices and soaring yields! Are these income shares an epic opportunity?

These income shares have taken a massive hit in 2025, but dividends continue to be paid, resulting in massive 9%…

Read more »